Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

NDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting ...

LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL'36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug ...

June 23, 2010 (Boca Raton, Florida) — Adding electroconvulsive therapy (ECT) to clozapine is an effective treatment for patients with clozapine-resistant schizophrenia, researchers reported at the New ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial investigating ...

Panelists discuss how prescription digital therapeutics can serve the psychological and social components of schizophrenia treatment while potentially improving medication adherence, similar to how ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...

Russia is facing a shortage of drugs which are used for the treatment of schizophrenia, psychosis, bipolar disorder, and ...